INSTITUTE CONFIDENTIALITY INSTITUTE REPRESENTATIVES PUBLICATIONS
PUBLICATIONS
July 2017
Trends in the molecular diagnosis of lung cancer, results from an online market research survey

Celine Audibert, Michael Shea, Daniel Glass, Marina Kozak, Alexis Caze, Ryan Hohman, Jeff Allen, Ellen V. Sigal, Jonathan Leff
FOCR
access article here
a b s t r a c t

Survey Goals:
To better understand the challenges that practices face in testing patients for oncogenic drivers, as well as the uptake of various testing technologies, a questionnaire was developed to obtain the opinions and experiences of practicing medical oncologists regarding the molecular testing process. Numerous specialties are involved in decisions about when and how to test patients and rarely does a single individual have full knowledge of all the steps in the process. However, as the primary point of contact with the patient, the medical oncologist was identified as the person most likely to provide insight into the entire process, from diagnosis, to testing, to treatment. The setting of non-small cell lung cancer (NSCLC) was identified as an area of focus due to the presence of multiple known oncogenic drivers and approved targeted agents, as well as the existence of several approved molecular diagnostics in that setting.